AnalystsDouglas MiehmDouglas Miehm's Stock Forecasts
AnalystsDouglas Miehm
Analyst Ranking
Top 27%
#1364 out of 5164 analysts
Average Return
+3.28%
Win Rate
54%22 out of 41
Risk vs Reward
Poor
Good
Douglas Miehm's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Ligand Pharmaceuticals IncLGND | +72.85% | $120.74 | $208.70 | 2024-11-12 - 2025-11-11 | Buy |
Mannkind CorpMNKD | +63.27% | $3.43 | $5.60 | 2025-08-07 - 2026-01-02 | Buy |
Aurinia Pharmaceuticals IncAUPH | +59.81% | $5.15 | $8.23 | 2022-11-04 - 2023-11-03 | Buy |
Oncolytics Biotech IncONCY | +53.27% | $0.64 | $0.98 | 2025-03-10 - 2026-01-02 | Buy |
Ligand Pharmaceuticals IncLGND | +52.90% | $120.36 | $184.03 | 2024-12-11 - 2025-12-10 | Buy |
Douglas Miehm Analyst Color
Get additional color on Douglas Miehm's coverage of popular stocks
Douglas Miehm's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Ligand Pharmaceuticals IncLGND | 8 | Buy | $235.00 | +23.61% | Maintains | a month ago |
Bausch & Lomb CorpBLCO | 14 | Buy | $19.00 | +14.60% | Maintains | 2 months ago |
Mannkind CorpMNKD | 4 | Buy | $7.50 | +33.93% | Maintains | 2 months ago |
Aurinia Pharmaceuticals IncAUPH | 10 | Hold | $15.00 | -2.28% | Downgrades | 2 months ago |
Bausch Health Companies IncBHC | 20 | Hold | $10.00 | +38.70% | Maintains | 8 months ago |
Oncolytics Biotech IncONCY | 1 | Buy | $5.00 | +408.13% | Maintains | 10 months ago |
Crh Medical CorpCRHM | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Novadaq Technologies IncNVDQ1 | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.